Clinical Trials Logo

Filter by:
NCT ID: NCT00528671 Terminated - Clinical trials for Mechanical Heart Valve Recipients

Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications

ESCAT III
Start date: January 2006
Phase: Phase 4
Study type: Interventional

We aim to investiagte whether very low dose self management of oral anticoagulation is superior to low dose oral anticoagulation in order to prevent bleeding events in patients undergoing mechanuical heart valve replacement.

NCT ID: NCT00522834 Terminated - Melanoma Clinical Trials

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Start date: August 2007
Phase: Phase 3
Study type: Interventional

"Elesclomol (STA-4783), N-malonyl-bis (N'-methyl-N'-thiobenzoylhydrazide) is a new chemical entity with a novel structure. STA-4783 induces an oxidative stress response in cells. This response is characterized by increased production of gene families that protect against different cellular stresses, including excessive heat, the presence of reactive oxygen species such as oxygen radicals, or the presence of heavy metals. Subjects will participate in up to 2 weeks of screening during which time they will complete all screening procedures. Eligible subjects who have not received any prior cytotoxic chemotherapeutic agent for melanoma will be randomized in a 1:1 ratio to receive either STA-4783 213 mg/m2 in combination with paclitaxel 80 mg/m2 or paclitaxel 80 mg/m2 alone. One treatment cycle will consist of weekly treatments for 3 weeks, followed by a 1-week rest period. Cycles will be repeated every 4 weeks until disease progression. Tumor assessments will be performed every 8 weeks from the date of randomization or sooner if the Investigator suspects progression has occurred based on clinical signs and symptoms. "

NCT ID: NCT00522418 Terminated - Epilepsy Clinical Trials

Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patients

Start date: February 2006
Phase: Phase 4
Study type: Interventional

This is a post-market medical device study. This study will compare best medical practice with or without adjunctive VNS Therapy in patients who are 16 years and older with pharmacoresistant partial epilepsy.

NCT ID: NCT00522171 Terminated - Obesity Clinical Trials

Harmonic Versus Electro Surgery in Lower Body Lift Procedures

LBL
Start date: September 2007
Phase: Phase 4
Study type: Observational

The objective of this study is to determine if the use of The Harmonicâ„¢ (an ultrasonic surgical instrument) in Lower Body Lift procedures reduces volume and duration of wound drainage after surgery when compared to Electro Surgery.

NCT ID: NCT00520520 Terminated - Clinical trials for Ventricular Fibrillation

Influence of Mild Therapeutic Hypothermia on Leukocyte Count

INCA
Start date: December 2009
Phase: N/A
Study type: Observational

Mild therapeutic hypothermia is indicated in patients surviving out-of-hospital cardiac arrest due to ventricular fibrillation. Potential immunologic responses are unknown.

NCT ID: NCT00520026 Terminated - Suicide Clinical Trials

Suicide Prevention by Lithium - the Lithium Intervention Study

SUPLI
Start date: January 2001
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the proposed suicide preventive effects of lithium in a randomized controlled trial within a group of individuals with depressive disorders. The hypothesis being tested is that lithium treatment will significantly reduce the risk for another suicide attempt.

NCT ID: NCT00519532 Terminated - Parkinson's Disease Clinical Trials

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Start date: July 2007
Phase: Phase 3
Study type: Interventional

The objective of this open-label extension is to assess the long-term effect of the 24-hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non-motor symptoms of Parkinson's disease. The long-term safety and tolerability of the rotigotine transdermal patch will also be evaluated.

NCT ID: NCT00519090 Terminated - Clinical trials for Myelogenous Leukemia

Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

ENEST
Start date: October 2007
Phase: Phase 3
Study type: Interventional

In this study, the efficacy and safety of nilotinib 400 mg twice daily, will be compared with imatinib 400 mg twice daily in patients with a suboptimal response to imatinib for their Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).

NCT ID: NCT00517192 Terminated - HIV Infections Clinical Trials

Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI

Start date: September 2007
Phase: Phase 3
Study type: Interventional

The objective of this study is to compare the efficacy and safety of Tipranavir/ritonavir (TPV/r, 500mg/200mg twice daily) to the safety and efficacy of Darunavir/ritonavir (DRV/r 600 mg /100 mg twice daily) in combination with investigator selected optimised background regimens in patients who are three-class (Nucleoside reverse transcriptase inhibitors (NRTI), Nonnucleoside reverse transcriptase inhibitors (NNRTI), and Protease inhibitor (PI)) treatment-experienced (a minimum of 3-months duration for each class) with resistance to more than one PI on the screening virtual phenotype resistance testing.

NCT ID: NCT00514917 Terminated - Prostatic Neoplasms Clinical Trials

A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)

Rising PSA
Start date: July 2007
Phase: Phase 3
Study type: Interventional

The primary objective was to evaluate and compare the efficacy of androgen deprivation with or without docetaxel as determined by the median progression free survival (PFS) over the period of 18-month therapy and at least 18-month follow-up. The secondary objectives were: - To assess cancer specific survival; - To compare overall survival between the 2 treatment groups; - To evaluate patient-reported outcomes including quality of life, fatigue, and sexual functioning as measured by 3 different assessments.